低级别胶质瘤同步替莫唑胺放化疗后的认知功能
本研究评估低级别胶质瘤患者术后接受同步及辅助替莫唑胺放化疗对神经认知功能的影响,37例患者完成基线评估,22例有基线与治疗后评估,结果显示除HVLT辨别力外所有心理测量指标组均值无统计学差异,认知功能在治疗后2年内保持稳定。
要点
- 37例低级别胶质瘤患者完成基线神经认知评估,22例有基线与放化疗后评估。
- 除HVLT辨别力外,所有心理测量指标基线与放化疗后组均值无统计学差异。
- 诊断时年龄>40岁及受教育年限>16年者基线言语记忆(HVLT评估)更优。
核心结论
- 低级别胶质瘤患者接受同步及辅助替莫唑胺放化疗后,前瞻性评估至2年认知功能保持稳定。
研究设计与样本
- 纳入术后接受放疗联合同步及辅助替莫唑胺治疗的成人低级别胶质瘤患者,在基线(放疗+替莫唑胺前)及治疗后不同时间间隔进行全套心理测量测试。
主要发现
- 37例低级别胶质瘤患者(平均年龄43.6岁,59.5%男性)完成基线神经认知评估。
- 诊断时年龄>40岁及受教育年限>16年的患者基线言语记忆(HVLT评估)更优。
- 按性别、年龄、教育史、癫痫病史、IDH突变状态及1p/19q共缺失状态分层,其他认知域未见差异。
- 22例患者完成基线与放化疗后神经认知评估,除HVLT辨别力外,所有心理测量指标基线与治疗后组均值无统计学差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to evaluate the effects of concurrent temozolomide-based chemoradiation therapy on neurocognitive function in patients with low-grade glioma (LGG). MATERIALS/METHODS: We included adult patients with LGG who were treated postoperatively with radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). Patients were evaluated with comprehensive psychometric tests at baseline (prior to RT + TMZ) and at various time intervals following RT + TMZ. Baseline cognitive performance was analyzed by sex, age, education history, history of seizures, IDH mutation status, and 1p/19q codeletion status. Changes in neurocognitive performance were evaluated over time. RESULTS: Thirty-seven LGG patients (mean age 43.6, 59.5% male) had baseline neurocognitive evaluation. Patients with an age > 40 years old at diagnosis and those with an education > 16 years demonstrated superior baseline verbal memory as assessed by HVLT. No other cognitive domains showed differences when stratified by the variables mentioned above. A total of 22 LGG patients had baseline and post RT + TMZ neurocognitive evaluation. Overall, patients showed no statistical difference between group mean test scores prior to and following RT + TMZ on all psychometric measures (with the exception of HVLT Discrimination). CONCLUSION: Cognitive function remained stable following RT + TMZ in LGG patients evaluated prospectively up to 2 years. The anticipated analysis of RTOG 0424 will provide valuable neurocognitive outcomes specifically for high risk LGG patients treated with RT + TMZ.
引用
- Park DY, Tom MC, Chen Y, et al. Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. J Neurooncol. 2022. PMID: 35486307. doi:10.1007/s11060-022-04019-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。